Advantage and Core Benefit
- Expected to have fewer side effects than immunosuppressive drugs that suppress normal immune responses
- Specific treatment of Th1 immune disorders such as contact dermatitis is possible
Background and Technology
Th1 cells are mainly induced by IFN-γ and IL-12, produce IFN-γ and IL-2, activate macrophages, and are involved in the elimination of intracellular parasites and inflammatory diseases. Dr. Shibuya’s group found that CD155 on CD4+ T cells acts as a co-stimulatory molecule, induces differentiation of naïve T cells into Th1 cells (left panel), and is involved in the pathogenesis of Th1 immune diseases.
By using CD155 inhibitory antibodies, the Th1/Th2 balance was tilted towards Th2, and the therapeutic effect on contact hypersensitivity (CHS), one of the Th1-type immune diseases, was found (right panel).
 |
Data
- CD155 co-stimulation promoted the differentiation of naive CD4+T cells into Th1 cells (human and mouse)
- Treatment with CD155 ligand-binding inhibitory antibodies has a therapeutic effect in a model of contact dermatitis (Type 5 allergy).
Patent and Publishment
JP 6296650 (Granted)
Y. Kanemaru et. al. J. Immunology (2015)
DOI: https://doi.org/10.4049/jimmunol.1401942
Researcher
Dr, Kazuko Shibuya and Dr. Akira Shibuya (Tsukuba University)
Expectations
We are looking for companies interested in developing therapeutics based on the mechanism of Th1/Th2 immune balance regulation by CD155. Co-development of humanized antibodies and collaborations for Th1 immune diseases are welcome. mCD155 antibody (TX56: rat IgG) hCD155 antibody (TX28: mouse IgG) MTA is available.
Product No. WL-03746